Meggle has launched the new high-functionality excipient (HFE) CombiLac, a lactose-based, co-processed excipient, specifically designed to ease oral solid dosage form development and manufacture in direct compression (DC).

CombiLac, an innovative, co-processed HFE consists of the spray-dried, ternary admixture of alpha-lactose monohydrate, MCC and starch, each conforming with Ph. Eur., USP-NF, and JP compendial requirements. A well-defined manufacturing process generates porous, spherical particles with a highly integrated structure, inseparable by physical means.

According to the company, CombiLac shows improved compaction properties compared to an equivalent blend of individual ingredients, providing robust tablets with minimal friability. Rapid, hardness-independent tablet disintegration for effective API release is achieved, in addition to powder flow characteristics necessary to enhance solid dosage form weight uniformity and throughput in tablet production.

CombiLac is designed for DC applications but may be also used in other formulation development approaches such as dry granulation. In production, release testing is reduced due to its ternary composition.